Literature DB >> 16325707

Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy.

Michael D Ober1, Lawrence A Yannuzzi, Diana V Do, Richard F Spaide, Neil M Bressler, Lee M Jampol, Allison Angelilli, Chiara M Eandi, Alice T Lyon.   

Abstract

PURPOSE: To report the use of photodynamic therapy with verteporfin as a treatment for patients with focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy (CSC).
DESIGN: Noncomparative, nonrandomized, retrospective interventional case series. PARTICIPANTS: Nine eyes of 9 symptomatic patients with acute focal retinal pigment epithelial leaks secondary to CSC, confirmed with fluorescein angiography, evaluated at 1 of 3 referral retina practices.
METHODS: Patients were treated with photodynamic therapy using verteporfin. Best-corrected visual acuity (VA) was recorded at presentation and follow-up visits. MAIN OUTCOME MEASURES: Resolution of neurosensory detachment, status of fluorescein leakage, and VA.
RESULTS: Neurosensory detachment and fluorescein leakage resolved in all patients within 1 month. Visual acuity improved from 1 to 6 lines in 7 eyes and remained unchanged in 2. At 6 months, there was a statistically significant improvement in mean VA (P = 0.012, Wilcoxon signed ranks test), and mean VA improved from 20/80 to 20/40. No patient lost vision or suffered any treatment-related complications.
CONCLUSION: The treatment of acute CSC with photodynamic therapy may result in prompt resolution of neurosensory detachment and fluorescein leakage, which can be associated with rapidly improved vision. Although this case series is limited in follow-up and number of patients, the encouraging results and lack of visually significant complications suggest that further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16325707     DOI: 10.1016/j.ophtha.2005.06.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  29 in total

1.  Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy.

Authors:  M J Koss; I Beger; F H Koch
Journal:  Eye (Lond)       Date:  2011-11-11       Impact factor: 3.775

2.  Effects of photodynamic therapy with verteporfin for the treatment of chronic central serous chorioretinopathy: An uncontrolled, open-label, observational study.

Authors:  Yildirim Bayezit Sakalar; Ugur Keklikci; Kaan Unlu; Mehmet Fuat Alakus; Ismail Hamdi Kara
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

3.  A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).

Authors:  Mitzy E Torres-Soriano; Gerardo García-Aguirre; Verónica Kon-Jara; Orlando Ustariz-Gonzáles; Maura Abraham-Marín; Michael D Ober; Hugo Quiroz-Mercado
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-04       Impact factor: 3.117

4.  Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up.

Authors:  A Arsan; H S Kanar; A Sonmez
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

5.  Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome.

Authors:  N K Yadav; C Jayadev; A Mohan; P Vijayan; R Battu; S Dabir; B Shetty; R Shetty
Journal:  Eye (Lond)       Date:  2015-01-23       Impact factor: 3.775

Review 6.  Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.

Authors:  H Q Lu; E Q Wang; T Zhang; Y X Chen
Journal:  Eye (Lond)       Date:  2015-10-30       Impact factor: 3.775

7.  [Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium].

Authors:  C Klatt; H Elsner; E Pörksen; R Brinkmann; A Bunse; R Birngruber; J Roider
Journal:  Ophthalmologe       Date:  2006-10       Impact factor: 1.059

8.  [Treatment of central serous chorioretinopathy: MicroPulse photocoagulation versus bevacizumab].

Authors:  I Beger; M J Koss; F Koch
Journal:  Ophthalmologe       Date:  2012-12       Impact factor: 1.059

9.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

10.  Prognostic factors related to photodynamic therapy for central serous chorioretinopathy.

Authors:  Jun Woong Moon; Hyeong Gon Yu; Tae Wan Kim; Hyung Chan Kim; Hum Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-07       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.